Cambrium Materials Platform
AI-powered molecular design platform for engineering high-performance materials
Platform · OtherCompany source
Company profile
About Cambrium
Cambrium is a materials science company that combines molecular biology, machine learning, protein engineering, and material science to design and produce high-performance materials. The company's platform uses molecular intelligence to predict how molecules will behave before they exist, then leverages living systems to build them at scale. Cambrium designs three core molecular systems—enzymes, polymers, and peptides—that can be applied across multiple industries. The company partners with organizations in apparel and footwear, personal care, mobility, home care, and building sectors to solve their most challenging performance problems. By working at the intersection of AI and bioscience, Cambrium creates materials that traditional chemistry cannot access, delivering products that outperform existing solutions. The company's approach is rooted in rigorous scientific methodology, combining curiosity with discipline to develop materials that embed themselves deeply into industries and carry them forward. Cambrium's team spans multiple scientific disciplines, united by the belief that better molecules can build a better world.
Company description Cambrium official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Cambrium?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Apparel & Footwear companies
- Building/Construction companies
- Home Care companies
- Mobility/Automotive companies
- Personal Care companies
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Developed multiple material products including RevaBond, Microcellular Foam, Protective Coating, and Midsole Foam
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Microcellular Foam
Advanced foam material for performance applications
Other · OtherCompany source
Midsole Foam
High-performance foam for footwear applications
Other · OtherCompany source
RevaBond
Engineered protective coating material
Other · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Divergent Transcriptional Architectures Beyond Core CAM Genes in Facultative and Constitutive CAM Species in Tillandsia L.Molecular ecology · Mar 1, 2026
CAM evolution is associated with gene family expansion in an explosive bromeliad radiation.The Plant cell · Oct 3, 2024
Death caps (Amanita phalloides) frequently establish from sexual spores, but individuals can grow large and live for more than a decade in invaded forests.The New phytologist · May 1, 2024
Dynamic lid domain of Chloroflexus aurantiacus Malonyl-CoA reductase controls the reaction.Biochimie · Apr 1, 2024
Invasive Californian death caps develop mushrooms unisexually and bisexually.Nature communications · Oct 24, 2023
The cofactor challenge in synthetic methylotrophy: bioengineering and industrial applications.Current opinion in biotechnology · Aug 1, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Material performance
Materials that outperform traditional chemistry solutions with unprecedented performance characteristics
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Mitchell Duffy
CEO
Charles Cotton
CSO
Pierre Salvy
CTO
Sam Tadman
Head of Polymers
Marla Rinne
Chief of Staff
06 · Company updates
Updates from Cambrium
Recent articles published on Cambrium's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.